Cornerstone Planning Group
RPRX icon

Cornerstone Planning Group’s Royalty Pharma RPRX Stock Holding History

Cornerstone Planning Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-373
Closed -$21.9K – 1367
2026
Q2 		$21.9K Sell
373
-29
-7% -$1.51K ﹤0.01% 653
2026
Q1 		$20.2K Buy
402
+106
+36% +$4.64K ﹤0.01% 663
2025
Q4 		$12K Sell
296
-235
-44% -$8.96K ﹤0.01% 748
2025
Q3 		$57.7K Buy
531
+406
+325% +$14.7K 0.01% 307
2025
Q2 		$4.74K Buy
125
+25
+25% +$828 ﹤0.01% 738
2025
Q1 		$3.17K Buy
100
+53
+113% +$1.68K ﹤0.01% 863
2024
Q4 		$1.49K Buy
+47
New +$1.25K ﹤0.01% 868

Other funds holding RPRX

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Hosking Partners
Hosking Partners London, United Kingdom $2.81B AUM 67.07% 1-Year Est. Return
Kepler Cheuvreux
Kepler Cheuvreux Nyon $1.65B AUM 36.86% 1-Year Est. Return
Foster Victor Wealth Advisors
Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return
Kirr Marbach & Co
Kirr Marbach & Co Columbus, Indiana $530M AUM 14.37% 1-Year Est. Return
Triasima Portfolio Management
Triasima Portfolio Management Montreal, Quebec, Canada $758M AUM 48.16% 1-Year Est. Return
Fideuram - Intesa Sanpaolo Private Banking
Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return

Cornerstone Planning Group's RPRX Position: Q3 2026 in Review

Cornerstone Planning Group sold out of Royalty Pharma (RPRX) in Q3 2026, closing a stake of 373 shares — an estimated $21.9K sold.

Cornerstone Planning Group first reported a position in RPRX in Q4 2024 and held it in 7 quarters. The position peaked at $57.7K in Q3 2025. 129 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Cornerstone Planning Group reported no remaining Royalty Pharma position as of Q3 2026 after selling out during the quarter.
  • Cornerstone Planning Group sold 373 Royalty Pharma shares in Q3 2026, an estimated $21.9K.
  • Cornerstone Planning Group first reported a position in Royalty Pharma in Q4 2024 and held it in 7 quarters.
  • Cornerstone Planning Group's Royalty Pharma position peaked at $57.7K in Q3 2025.
  • 129 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Cornerstone Planning Group's 13F filing for Q3 2026, filed 16 Oct 2026.